← Issue №19/ week of Nov 8, 2026/IBD

Clinical features and outcomes of perianal disease in pediatric-onset Crohn's disease: A comparative analysis according to age at diagnosis.

From GI Signals issue №19: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD retrospective · n=144 · Nov 3, 2026 · BMC Gastro · IF 2.5

Clinical features and outcomes of perianal disease in pediatric-onset Crohn's disease: A comparative analysis according to age at diagnosis.

New evidencepediatricperianal diseaseCrohn's diseasebiologics
Clinical takeawayConsider genetic testing for monogenic mutations, particularly IL-10RA, in VEO-IBD patients with perianal disease. Thalidomide and/or HSCT may be individualized options for selected monogenic VEO-IBD patients, but avoid generalizing thalidomide to all VEO-IBD.
What it foundVEO-IBD with PD had a monogenic mutation rate of 77.27% (17/22), predominantly IL-10RA, and lower clinical remission (71.93% vs 95.40% in non-PD).
ContextConfirms that VEO-IBD with PD is associated with monogenic mutations and poorer outcomes, refining prior evidence on disease severity and treatment response in pediatric CD. Highlights the need for cautious use of thalidomide in this population.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Mi M … Zhong X · BMC Gastroenterology · IF 2.5 · PubMed ↗Permalink
← Read the whole of issue №19 Every paper GI Signals surfaces gets a page like this one. All issues